12/4 In Vitro
Surnar et al., ACS Pharmacol. Transl. Sci., doi:10.1021/acsptsci.0c00179 (Peer Reviewed) (In Vitro)
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19
In Vitro analysis of ivermectin with orally administrable nanoparticles showing efficacy for decreasing expression of the viral spike protein and ACE2. Inhibition of nuclear transport activities mediated through proteins such as importin α/β1 heterodimer are also considered as a possible mechanism of action. The technology may work for other coronaviruses as well.
Surnar et al., 12/4/2020, peer-reviewed, 4 authors.
Please send us corrections, updates, or comments.
Submit